Creating and Providing Innovative Drugs and Services
As stated in its Mission, Chugai seeks to contribute to the medical community and human health around the world by providing innovative drugs and services.
Until now, Chugai has created and delivered innovative drugs based on its drug discovery and production technologies, focusing primarily on biopharmaceuticals and small-molecule drugs. However, as the creation of novel drugs becomes increasingly difficult, we need to focus even more strongly on innovation. In addition to our existing technological infrastructure, we are establishing a technology platform for middle-molecule drugs, our next-generation core technology, deepening our understanding of clinical conditions, and pursuing innovation of the drug discovery process. Through these and other initiatives, we will aim to contribute to the cure and complete control of diseases that have long been considered difficult to treat.
Our contribution to patients does not end with providing medicine. To make sure that those medicines are used appropriately, it is essential to provide information to properly inform healthcare professionals of the value of our products, and to collect, analyze and share extensive safety information so that our products can be used confidently at the point of care. To that end, we will also use digital technology to enable patients to visualize the true value provided by our effective, efficient solutions.
Enabling Patient-Centric Personalized Healthcare
Personalized healthcare (PHC), in which treatment plans are prepared according to each patient’s genetic profile, is an approach that contributes to “advanced and sustainable patient-centric healthcare.” PHC offers value for patients, payers and society because only patients who can be expected to benefit from a particular medicine or treatment are given that treatment. Recently, further advances have been made in PHC, supported by rapid progress in genomic medicine and data analysis technology. Timely acquisition of patient data will make it possible to quickly measure and evaluate not only the efficacy and safety of drugs but a wide range of other information, including their impact on quality of life.
As a member of the Roche Group, which is a global leader in PHC, and as a pioneer of PHC in Japan, Chugai is focusing on promoting a new phase of PHC to provide the optimal treatment to each individual patient. We work closely with the national government and academic institutions, in addition to collaborating with other Roche Group companies, including Flatiron Health, to build a comprehensive database for use in clinical practice.
Establishment of an Advanced Drug Safety System
To ensure that the innovative products Chugai handles are used appropriately and confidently at the point of care worldwide, it is vital that we gather and analyze safety information and provide relevant information to healthcare professionals. To that end, we established the Drug Safety Division as an independent unit, and created a safety assurance system directly linked to management. We have also established a framework for collecting safety information at the global level in cooperation with Roche and other partners.
Chugai is committed to highly transparent and prompt reporting and release of drug safety information. We evaluate the large volume of drug safety information we collect from around the world from a medical point of view, and simultaneously utilize advanced information technology to record the information in a database. Using that database, we conduct signal detection of adverse drug reactions, and promptly consult with regulatory authorities in various countries regarding safety measures. We also use database tools to quickly deliver relevant information to healthcare professionals.
Evolution of Quality Management
In the pharmaceutical business, it is vital that we ensure the quality of both products and information so that drugs can be used safely and with peace of mind. Therefore, quality, including accuracy, is required in the information we deliver to medical professionals, not to mention the products we provide. In addition, the quality of our business processes for providing products and information is important, as is the awareness and behavior of the employees who implement those processes. We will also strengthen risk management and compliance, which underpin that awareness and behavior.
Furthermore, improving quality requires not only our own efforts but also cooperation from our business partners. To enhance quality standards on a global level, we will foster and instill a quality-oriented culture while taking an active role in ensuring the quality of our business partners.
Marketing Aimed at Development of Regional Healthcare
At Chugai, we are responsible for addressing issues from the onset of the patient’s disease to screening, testing and diagnosis, prescription and treatment adherence in all disease areas. That is why we are focusing on helping to enhance healthcare delivery systems in every region of Japan.
To support that effort, we have created a database compiled from real-world data, including incidence rates, examination rates, diagnosis rates, availability of testing platforms, sales of various pharmaceuticals and treatment adherence rates. This database enables us to visualize the flow of patients and the coordination of care among medical institutions. Based on that information, we act as a regional healthcare liaison in order to solve healthcare issues specific to each region. In this role, we support cooperation among regional medical professionals and medical institutions, as well as collaboration with local governments, public organizations and companies in different industries, and take measures to help improve patient access to care. We are also devoting efforts to disease awareness campaigns in cooperation with governments and other organizations.